129789-59-9

Basic information

• Product Name: (6-PHTHALIMIDOHEXYL)TRIPHENYLPHOSPHONIUM BROMIDE
• Synonyms: 6-(1,3-dioxoisoindolin-2-yl)hexyl-triphenyl-phosphonium bromide
• CAS NO: 129789-59-9
• Molecular Formula: Br*C₃₂H₃₁NO₂P
• Molecular Weight: 0
• Mol File: 129789-59-9.mol

Chemical Properties

• Melting Point: 74-76°C
• Appearance: /
• Sensitive: Hygroscopic
• CAS DataBase Reference: (6-PHTHALIMIDOHEXYL)TRIPHENYLPHOSPHONIUM BROMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: (6-PHTHALIMIDOHEXYL)TRIPHENYLPHOSPHONIUM BROMIDE(129789-59-9)
• EPA Substance Registry System: (6-PHTHALIMIDOHEXYL)TRIPHENYLPHOSPHONIUM BROMIDE(129789-59-9)

Safety Data

• Hazardous Substances Data: 129789-59-9(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
(6-PHTHALIMIDOHEXYL)TRIPHENYLPHOSPHONIUM BROMIDE is used as a reactant for its ability to participate in various organic reactions, such as nucleophilic substitutions, alkylations, and Michael additions. Its unique structure allows it to act as a catalyst, enhancing the efficiency and selectivity of these reactions.
Used in Pharmaceutical Preparation:
In the pharmaceutical industry, (6-PHTHALIMIDOHEXYL)TRIPHENYLPHOSPHONIUM BROMIDE is used as a reactant in the preparation of various organic compounds and pharmaceuticals. Its versatility in facilitating different types of chemical reactions makes it a valuable component in the synthesis of a wide array of medicinal compounds.
Used as a Phase Transfer Catalyst:
(6-PHTHALIMIDOHEXYL)TRIPHENYLPHOSPHONIUM BROMIDE is utilized as a phase transfer catalyst to expedite reactions between reactants in two immiscible phases, typically an aqueous and an organic phase. This property is particularly useful in industrial processes where efficient mixing and reaction rates are crucial for the production of desired compounds.

InChI:InChI=1/C32H31NO2P.BrH/c34-31-29-22-12-13-23-30(29)32(35)33(31)24-14-1-2-15-25-36(26-16-6-3-7-17-26,27-18-8-4-9-19-27)28-20-10-5-11-21-28;/h3-13,16-23H,1-2,14-15,24-25H2;1H/q+1;/p-1

Upstream product

• 24566-79-8 2-(6-bromohexyl)isoindole-1,3-dione 
• 603-35-0 triphenylphosphine 
• 85-44-9 phthalic anhydride 
• 4048-33-3 6-amino-1-hexanol 
• 63945-11-9 6-phthalimido-1-hexanol 
• 136918-14-4 phthalimide 
• 629-03-8 1 ,6-dibromohexane 

Downstream Products

• 1205553-15-6 [1-(4-biphenylyl)-7-phthalimido]-1-heptene 

Relevant articles and documents

SYNERGISTIC INIHIBITION OF TUMOR CELL PROLIFERATION INDUCED BY COMBINED TREATMENT OF METFORMIN COMPOUNDS AND IRON CHELATORS

The present invention is directed to combination therapy comprising metformin or mito-metformin compounds with at least one iron chelating agent for the treatment of cancer and pharmaceutical compositions thereof.

MODIFIED MITO-METFORMIN COMPOUNDS AND METHODS OF SYNTHESIS AND USE THEREOF

The present invention provides mito-metformin compounds, pharmaceutical compositions thereof, and methods of using the mito-metformin compounds in the treatment of cancer.

Phosphonium lipocations as antiparasitic agents

Phosphonium lipocations were synthesized and evaluated for inhibition of the development of Plasmodium falciparum and Trypanosoma cruzi, etiological agents of malaria and Chagas disease, respectively. Optimal phthalimides and 1,4-naphthoquinone-based lipocations were active in vitro at mid-high nM concentrations against P. falciparum and low μM concentrations against T. cruzi.

ENZYME INHIBITORS AND THE USE THEREOF

The present invention provides compounds and methods for the treatment of diseases or disorders such as heart failure, hyperlipidemia, hypercholesterolemia, gonadotropin deficiency, diabetes mellitus, metabolic syndrome, hyperglycemia, insulin resistance,

Synthesis of bridged dinucleosides

A series of di-(adenosin-N6-yl) alkanes (1b) - (11) has been prepared by reaction of the appropriate diaminoalkanes with 6-chloro-9-β-D-(2,3,5-tri-O-acetyl)-ribofuranosyl-purine (2) followed by ammonolysis. Alternatively, an analogous reaction with 6-chloro-9-β-D-(2,3-O-isopropylidene)-ribofuranosylpurine (3) produced an intermediate which could be phosphorylated at the 5′-position prior to hydrolytic removal of the isopropylidene group. 4-(1,2,4-Triazolo)-1-(β-D-2,3,5-tri-O-acetyl ribofuranosyl)-2(1H)-pyrimidone (7) was an effective intermediate for the preparation of di-(cytidin-N4-yl) alkanes (8a), (8b), and (8c) from the appropriate diaminoalkanes. The longer chain di-(adenosin-N6-yl) alkanes are very effective inhibitors of adenosine kinase. In addition an approach to the di-(adenosin-N6-yl) alkanes is described which should allow tritium labelling of the alkyl chain.